Cargando…

Combination of Aflibercept and Bromfenac Therapy in Age-Related Macular Degeneration: A Pilot Study Aflibercept and Bromfenac in AMD

BACKGROUND: Among many protocols for treatment of exudative AMD, combined therapy of anti-VEGF agents and non-steroidal anti-inflammatory drugs (NSAIDs) seems to be an ideal alternative to monotherapy based on ranibizumab or bevacizumab. The aim of this study was to evaluate the effectiveness of afl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wyględowska-Promieńska, Dorota, Piotrowska-Gwóźdź, Anna, Piotrowska-Seweryn, Agnieszka, Mazur-Piotrowska, Grażyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2015
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687982/ https://www.ncbi.nlm.nih.gov/pubmed/26667262 http://dx.doi.org/10.12659/MSM.895977

Ejemplares similares

Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: A pilot study
por: Wyględowska-Promieńska, Dorota, et al.
Publicado: (2014)

The Effect of Topical Bromfenac on Intraretinal and Subretinal Fluid in Neovascular Age-Related Macular Degeneration
por: Abdolrahimzadeh, Solmaz, et al.
Publicado: (2020)

Bromfenac 0.09% for the Treatment of Macular Edema Secondary to Noninfectious Uveitis
por: Saade, Joanna S., et al.
Publicado: (2021)

Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema
por: Gabr, Ahmed F., et al.
Publicado: (2023)

Aflibercept for the Treatment of Age-Related Macular Degeneration
por: Trichonas, George, et al.
Publicado: (2013)

Bromfenac-induced neurotrophic keratitis in a corneal graft
por: Raj, Nimmy, et al.
Publicado: (2022)

Ziv-aflibercept in macular disease
por: Mansour, Ahmad M, et al.
Publicado: (2015)

Two-Year Outcome of Aflibercept in Patients with Pigment Epithelial Detachment due to Neovascular Age-Related Macular Degeneration (nAMD) Refractory to Ranibizumab
por: Tran, Thi Ha Chau, et al.
Publicado: (2017)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
por: Rowe, Lucas W., et al.
Publicado: (2023)

Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review
por: Sheppard, John D
Publicado: (2016)

Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes
por: Song, Seok Hyeon, et al.
Publicado: (2020)

Topical Bromfenac Sodium in Femtosecond Laser-Assisted Cataract Surgery
por: Aguilar Sierra, María Camila, et al.
Publicado: (2020)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
por: Ferrante, Nicola, et al.
Publicado: (2022)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
por: Nowosielska, Agnieszka
Publicado: (2019)

Effects of Topical Prostaglandin Analog on Macular Thickness Following Cataract Surgery with Postoperative Topical Bromfenac Treatment
por: Park, Kee Sup, et al.
Publicado: (2020)

Corneal sensitivity after topical bromfenac sodium eye-drop instillation
por: Yanai, Kaori, et al.
Publicado: (2013)

Aflibercept in wet AMD: specific role and optimal use
por: Semeraro, F, et al.
Publicado: (2013)

Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Gharbiya, Magda, et al.
Publicado: (2014)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
por: Luksa, Dorota, et al.
Publicado: (2021)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration
por: Tamiya, Ryosuke, et al.
Publicado: (2023)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Topical bromfenac reduces multiple inflammatory cytokines in the aqueous humour of pseudophakic patients
por: Matsumura, Takehiro, et al.
Publicado: (2021)

Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
por: Ali Said, Yasmin, et al.
Publicado: (2022)

Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
por: Neves Cardoso, Pedro, et al.
Publicado: (2017)

Lentiviral delivered aflibercept OXB-203 for treatment of neovascular AMD
por: Iqball, Sharifah, et al.
Publicado: (2023)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Different Impacts of Luminosity on Contrast Vision in Eyes with Transparent Optic Media and with Cataract Simulation
por: Smedowski, Adrian, et al.
Publicado: (2015)

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
por: Thomas, Michael, et al.
Publicado: (2013)

Rescue effects of intravitreal aflibercept in the treatment of neovascular age-related macular degeneration
por: Hsia, Ning-Yi, et al.
Publicado: (2015)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg, Justus G
Publicado: (2019)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
por: Lee, Junyeop, et al.
Publicado: (2022)

Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
por: Gyenes, Andrea, et al.
Publicado: (2023)

Off-Label Uses of Ranibizumab and Aflibercept for Age-Related Macular Degeneration in Turkey
por: Yilmaz, Mevlut, et al.
Publicado: (2023)

Appropriateness of quality standards for meaningful intercentre comparisons of aflibercept service provision for neovascular age-related macular degeneration
por: Talks, J S, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_52vpfdu90jjelhjpsetkeb7orp